{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:56:46Z","timestamp":1790909806820,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"gs1:Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","award":["#140907\/2013-0"],"award-info":[{"award-number":["#140907\/2013-0"]}]},{"name":"gs2:Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","award":["#15\/10436-6"],"award-info":[{"award-number":["#15\/10436-6"]}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["#15\/24595-9"],"award-info":[{"award-number":["#15\/24595-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["#309764\/2015-7"],"award-info":[{"award-number":["#309764\/2015-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"publisher","award":["#2014\/21129-4"],"award-info":[{"award-number":["#2014\/21129-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijpddr.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T14:25:12Z","timestamp":1538144712000},"page":"430-439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis"],"prefix":"10.1016","volume":"8","author":[{"given":"Laura M.","family":"Alc\u00e2ntara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8282-5708","authenticated-orcid":false,"given":"Thalita C.S.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo C.","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2018.09.006_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: M\u00e9decins Sans Fronti\u00e8res experience in the Democratic Republic of the Congo","volume":"56","author":"Alirol","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol. Drugs drug Resist."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1087057114555846","article-title":"High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease","volume":"20","author":"Annang","year":"2015","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15406\/mojbb.2017.03.00044","article-title":"Target product profile: a planning tool for the drug development","volume":"3","author":"Bandyopadhyay","year":"2017","journal-title":"MOJ Bioequivalence Bioavailab"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(03)14694-6","article-title":"The trypanosomiases","volume":"362","author":"Barrett","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bmb\/lds031","article-title":"Management of trypanosomiasis and leishmaniasis","volume":"104","author":"Barrett","year":"2012","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib8","doi-asserted-by":"crossref","first-page":"e1625","DOI":"10.1371\/journal.pntd.0001625","article-title":"Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs","volume":"6","author":"Bell","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4269\/ajtmh.16-0099","article-title":"The tropical disease priority review voucher: a game-changer for tropical disease products","volume":"96","author":"Berman","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2016.12.016","article-title":"A new epoch in antitrypanosomal treatment for Chagas disease","volume":"69","author":"Bern","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-3024.2009.01102.x","article-title":"Genetics and visceral leishmaniasis: of mice and man","volume":"31","author":"Blackwell","year":"2009","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cmdc.200700139","article-title":"Lessons learnt from assembling screening libraries for drug discovery for neglected diseases","volume":"3","author":"Brenk","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib13","doi-asserted-by":"crossref","first-page":"e0005781","DOI":"10.1371\/journal.pntd.0005781","article-title":"Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: a first step to assess the feasibility of establishing an individual patient data sharing platform","volume":"11","author":"Bush","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/0074-02760160100","article-title":"Experimental infection of Phlebotomus perniciosus by bioluminescent Leishmania infantum using murine model and artificial feeder","volume":"111","author":"Cannet","year":"2016","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1073\/pnas.0704384105","article-title":"Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development","volume":"105","author":"Cavazzuti","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art","volume":"145","author":"Charlton","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib17","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib18","doi-asserted-by":"crossref","first-page":"e0004660","DOI":"10.1371\/journal.pntd.0004660","article-title":"A luciferase-expressing Leishmania braziliensis line that leads to sustained skin lesions in BALB\/c mice and allows monitoring of miltefosine treatment outcome","volume":"10","author":"Coelho","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0169-4758(86)90157-2","article-title":"In vitro screens in the experimental chemotherapy of leishmaniasis and trypanosomiasis","volume":"2","author":"Croft","year":"1986","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib21","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"Croft","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib22","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/AAC.02398-12","article-title":"Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay","volume":"57","author":"De Rycker","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","article-title":"Leishmaniasis impact and treatment access","volume":"17","author":"den Boer","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib24","article-title":"Target product profile \u2013 cutaneous leishmaniasis","author":"DNDi","year":"2018","journal-title":"Drugs neglected Dis. Initiat"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib25","article-title":"Target product profile \u2013 visceral leishmaniasis","author":"DNDi","year":"2018","journal-title":"Drugs neglected Dis. Initiat"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib26","article-title":"DNDi portfolio June 2018","author":"DNDi","year":"2018","journal-title":"Drugs neglected Dis. Initiat"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib27","unstructured":"Drug Discovery Unit, University of Dundee [WWW Document], 2018. URL http:\/\/www.drugdiscovery.dundee.ac.uk\/portfolio\/diseases-developing-world (accessed 8.20.2018)."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib28","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1128\/AAC.00021-16","article-title":"From drug screening to target Deconvolution: a target-based drug discovery pipeline using Leishmania casein kinase 1 isoform 2 to identify compounds with antileishmanial activity","volume":"60","author":"Durieu","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib29","unstructured":"EMBL-EBI, 2018. No title [WWW Document]. Eur. Bioinforma. Inst. URL https:\/\/www.ebi.ac.uk\/training\/online\/course\/chembl-quick-tour\/what-chembl (Accessed 1 August 2018)."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib30","unstructured":"FDA, 2017. No title [WWW Document]. U.S. Food drug adm. URL https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209570lbl.pdf (Accessed 20 August 2018)."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib31","unstructured":"FDA, 2014. No title [WWW Document]. U.S. Food drug adm. URL https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204684s000lbl.pdf (Accessed 1 August 2018)."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"10.1016\/j.ijpddr.2018.09.006_bib33","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00520-15","article-title":"Limited ability of Posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging","volume":"59","author":"Francisco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?","volume":"2","author":"Freitas-Junior","year":"2012","journal-title":"Int. J. Parasitol. Drugs drug Resist."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib35","first-page":"439","article-title":"Animal models for vaccine studies for visceral leishmaniasis","volume":"123","author":"Garg","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib36","author":"GHIT fund"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib37","doi-asserted-by":"crossref","first-page":"11131","DOI":"10.1021\/cr500546h","article-title":"Introduction: drug discovery and development for neglected diseases","volume":"114","author":"Goupil","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib38","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1377\/hlthaff.28.6.1745","article-title":"Progress in public-private partnerships to fight neglected diseases","volume":"28","author":"Gustavsen","year":"2009","journal-title":"Health Aff."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib39","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib40","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/S0140-6736(09)60233-6","article-title":"Rescuing the bottom billion through control of neglected tropical diseases","volume":"373","author":"Hotez","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/521682","article-title":"Genetic predisposition to self-curing infection with the protozoan Leishmania chagasi: a genomewide scan","volume":"196","author":"Jeronimo","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acsinfecdis.7b00244","article-title":"Genetically validated drug targets in Leishmania: current knowledge and future prospects","volume":"4","author":"Jones","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13071-018-2634-x","article-title":"A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda","volume":"11","author":"Kansiime","year":"2018","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2915.1990.tb00255.x","article-title":"Phlebotomine vectors of the leishmaniases: a review","volume":"4","author":"Killick-Kendrick","year":"1990","journal-title":"Med. Vet. Entomol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1462-5822.2004.00468.x","article-title":"Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice","volume":"7","author":"Lang","year":"2005","journal-title":"Cell Microbiol."},{"issue":"9","key":"10.1016\/j.ijpddr.2018.09.006_bib47","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/cmi.12297","article-title":"Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection","volume":"16","author":"Lewis","year":"2014","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrg2778","article-title":"The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts","volume":"11","author":"MacLean","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib49","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jac\/dkw409","article-title":"In vitro \u201ctime-to-kill\u201d assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum","volume":"72","author":"Maes","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003889","article-title":"A review: the current in vivo models for the discovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis","volume":"9","author":"Mears","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005924","article-title":"New insights into experimental visceral leishmaniasis: real-time in vivo imaging of Leishmania donovani virulence","volume":"11","author":"Melo","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"1","key":"10.1016\/j.ijpddr.2018.09.006_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijantimicag.2011.03.012","article-title":"Clinical isolates of New World Leishmania from cutaneous and visceral leishmaniasis patients are uniformly sensitive to tamoxifen","volume":"38","author":"Miguel","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib53","author":"MMV Malaria Box","year":"2018","journal-title":"Med. Malar. Ventur"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib54","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib55","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and posaconazole in eliminating parasites in asymptomatic T. Cruzi carriers: the STOP-CHAGAS trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/1566524043360069","article-title":"Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host","volume":"4","author":"Naderer","year":"2004","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib57","unstructured":"NIH, 2018. No tit [WWW Document]. Natl. Inst. Heal. URL https:\/\/www.ninds.nih.gov\/funding\/apply-funding\/application-support-library\/create-bio-example-target-product-profile-tpp (Accessed 20 August 2018)."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004094","article-title":"Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity","volume":"9","author":"N\u00fchs","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib59","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2174\/092986710790979953","article-title":"Trypanosomatid parasites causing neglected diseases","volume":"17","author":"Nussbaum","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1538\/expanim.52.109","article-title":"Applications of recombinant Leishmania amazonensis expressing egfp or the beta-galactosidase gene for drug screening and histopathological analysis","volume":"52","author":"Okuno","year":"2003","journal-title":"Exp. Anim."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.mimet.2016.08.003","article-title":"In vivo near-infrared fluorescence imaging of Leishmania amazonensis expressing infrared fluorescence protein (iRFP) for real-time monitoring of cutaneous leishmaniasis in mice","volume":"130","author":"Oliveira","year":"2016","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib62","unstructured":"Pathogen Box 2018. No title [WWW Document]. Med. Malar. Ventur. URL https:\/\/www.pathogenbox.org (Accessed 1 August 2018)."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib63","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.pmed.0010006","article-title":"New drugs for neglected diseases: from pipeline to patients","volume":"1","author":"P\u00e9coul","year":"2004","journal-title":"PLoS Med."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib64","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment","volume":"1","author":"Pedrique","year":"2013","journal-title":"Lancet. Glob. Heal."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib65","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource","volume":"5","author":"Pe\u00f1a","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib66","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4269\/ajtmh.2010.09-0620","article-title":"Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus","volume":"82","author":"Pinazo","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib67","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd1824","article-title":"Opportunities and challenges in antiparasitic drug discovery","volume":"4","author":"Pink","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/pgmj.2006.047340corr1","article-title":"Leishmaniasis","volume":"83","author":"Piscopo","year":"2007","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib70","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1128\/AAC.02022-13","article-title":"Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection","volume":"58","author":"Rachidi","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib71","doi-asserted-by":"crossref","first-page":"e0005635","DOI":"10.1371\/journal.pntd.0005635","article-title":"Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh","volume":"11","author":"Rahman","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijpddr.2014.05.001","article-title":"Target-based vs. phenotypic screenings in Leishmania drug discovery: a marriage of convenience or a dialogue of the deaf?","volume":"4","author":"Reguera","year":"2014","journal-title":"Int. J. Parasitol. Drugs drug Resist."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003556","article-title":"Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging","volume":"9","author":"Reim\u00e3o","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4269\/ajtmh.16-0600","article-title":"Priorities for the priority review voucher","volume":"96","author":"Ridley","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.diagmicrobio.2012.11.018","article-title":"An alternative in vitro drug screening test using Leishmania amazonensis transfected with red fluorescent protein","volume":"75","author":"Rocha","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib76","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.parint.2016.10.020","article-title":"Imaging visceral leishmaniasis in real time with golden hamster model: monitoring the parasite burden and hamster transcripts to further characterize the immunological responses of the host","volume":"66","author":"Rouault","year":"2017","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib77","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.micro.55.1.453","article-title":"Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis","volume":"55","author":"Sacks","year":"2001","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0166-6851(86)90001-0","article-title":"Mechanism of action of amphotericin B on Leishmania donovani promastigotes","volume":"19","author":"Saha","year":"1986","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.pt.2009.05.004","article-title":"The role of host genetics in leishmaniasis","volume":"25","author":"Sakthianandeswaren","year":"2009","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib80","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/jac\/dkp500","article-title":"In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent","volume":"65","author":"Seifert","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib81","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4269\/ajtmh.2004.71.400","article-title":"Short report: fluorescent Leishmania: application to anti-leishmanial drug testing","volume":"71","author":"Singh","year":"2004","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","article-title":"Leishmaniasis: current status of available drugs and new potential drug targets","volume":"5","author":"Singh","year":"2012","journal-title":"Asian Pac. J. Trop. Med."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib83","doi-asserted-by":"crossref","first-page":"e1671","DOI":"10.1371\/journal.pntd.0001671","article-title":"An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages","volume":"6","author":"Siqueira-Neto","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib84","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1371\/journal.pntd.0000675","article-title":"Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds","volume":"4","author":"Siqueira-Neto","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib85","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib86","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vetpar.2011.12.035","article-title":"Leishmania tropica experimental infection in the rat using luciferase-transfected parasites","volume":"187","author":"Talmi-Frank","year":"2012","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib87","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0031182013000450","article-title":"N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis","volume":"141","author":"Tate","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib88","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1128\/AAC.01781-15","article-title":"A replicative in vitro assay for drug discovery against Leishmania donovani","volume":"60","author":"Tegazzini","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib89","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/AAC.01315-13","article-title":"Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis","volume":"58","author":"Trinconi","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib90","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"Trouiller","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib91","first-page":"1","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"145","author":"Uliana","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib92","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jac\/dky014","article-title":"Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages","volume":"73","author":"Voak","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib93","doi-asserted-by":"crossref","first-page":"e1033","DOI":"10.1371\/journal.pntd.0001033","article-title":"High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase","volume":"5","author":"Walker","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib94","series-title":"Leishmaniasis","author":"WHO","year":"2018"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib95","series-title":"Contribution of Pharmaceutical Companies To The Control Of Neglected Tropical Diseases","author":"WHO","year":"2018"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib96","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2174\/156802611795429185","article-title":"Target validation: linking target and chemical properties to desired product profile","volume":"11","author":"Wyatt","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"issue":"7717","key":"10.1016\/j.ijpddr.2018.09.006_bib97","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral Leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib98","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1371\/journal.pntd.0000720","article-title":"NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness","volume":"4","author":"Yun","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib99","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.tibtech.2010.02.005","article-title":"High content screening: seeing is believing","volume":"28","author":"Zanella","year":"2010","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ijpddr.2018.09.006_bib100","first-page":"68","article-title":"In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B","volume":"15","author":"Zauli-Nascimento","year":"2010","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ijpddr.2018.09.006_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22101715","article-title":"Screening a natural product-based library against kinetoplastid parasites","volume":"22","author":"Zulfiqar","year":"2017","journal-title":"Molecules"}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132071830071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132071830071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:48:54Z","timestamp":1761922134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221132071830071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S221132071830071X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2018.09.006","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}